Silverfleet Capital invests in CARE Fertility
Founded in 1997, CARE Fertility operates nine CARE branded clinics and 13 satellite facilities providing extensive coverage across the UK and the Republic of Ireland. Since its formation CARE has aided the conception of over 30,000 babies, among the highest success rates across all key metrics in the UK. With extensive R&D operations, CARE has become an industry innovator, using data analysis and clinical expertise to bring pioneering treatments and procedures to market.
CARE is the UK’s only fully integrated, centrally controlled and branded platform supporting continued rapid growth while maintaining operational excellence. CARE Fertility is renowned for innovation and their involvement in a number of industry and world firsts in the IVF sector.
CARE marks another Healthcare sector investment for Silverfleet and continues Silverfleet’s tradition of backing high growth, high potential Healthcare businesses. With Silverfleet’s support, CARE expects to continue its strong growth in the UK market, while also moving into international markets, leveraging its expertise and scaleable operating model.
Alfa Chan, Partner at Silverfleet commented:
“Lincoln’s sector knowledge and relationships within the IVF space are second to none and Matt’s knowledge of the business and stakeholders helped at a number of crucial points of the deal. We were delighted with the support we received so hope this is the first of many interactions with the Lincoln Healthcare team.”
Lincoln acted as the exclusive financial adviser to Silverfleet working closely with the Silverfleet deal team to manage the transaction from initial offer through to signing. As part of this, Lincoln were intimately involved in lending its global and extensive clinic and fertility expertise, supporting the day-to-day execution of the deal, while also providing bidder and process intelligence and guiding on tactical aspects to ultimately pre-empt the process and secure the deal for Silverfleet.
Matthew Lee, Lincoln UK Head of Healthcare commented:
“We are delighted to have advised Silverfleet on this transaction and continue Lincoln’s record in the fertility market. Having led the sale of CARE to Bowmark in 2012, it has been fantastic seeing the continued growth of the company to this point. CARE is a differentiated business with huge growth potential which is now looking forward to the exciting next phase of growth in partnership with Silverfleet.”
Meet our Senior Team
View More Transactions
Lincoln International is pleased to announce the successful sale of C³ (Cannabinoid Compound Company), a subsidiary of Bionorica SE, a producer and marketer of cannabis-based therapeutic compounds, to Canopy Growth
Lincoln is pleased to announce that it has advised Riello Investimenti SGR on the sale of Trafimet Group to Kemppi Oy
Lincoln International is pleased to have advised Tikehau Capital on its £23 million minority investment into Medtrade, a UK based manufacturer of advanced woundcare and consumer healthcare products
Lincoln International is pleased to announce the successful completion of a $20 million Series C financing round for Rapid Medical